AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00923260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux-en-Y Gastric Bypass
Description: Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
Study NCT00923260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y Gastric Bypass
Description: Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
Study NCT00923260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omentectomy
Description: After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
Study NCT00477360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humeral surface replacement hemiarthroplasty (CAP)
Description: C.A.P hemiarthroplasty
Study NCT03470246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACO intervention for CABG patients
Description: The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from coronary artery bypass grafting (CABG). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
Study NCT03470246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACO intervention for AVR patients
Description: The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from aortic valve replacement (AVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
Study NCT03470246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACO intervention for MVR patients
Description: The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from mitral valve repair (MVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
Study NCT02116673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive rest
Description: The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
Study NCT02116673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
Study NCT02766192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02766192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIMBER Psychotherapy
Study NCT02766192 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TIMBER Psychotherapy
Study NCT02766192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Study NCT03644953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.
Study NCT01794988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NO TIVR
Description: Control - no intervention
Study NCT00681629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: 400-800 mg, oral, bid
Study NCT00681629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Care Program (ICP)
Description: Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
Study NCT00956917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Akern USA EFG
Description: Impedance measurement device
Study NCT00956917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RJL Impedance analyzer
Description: Impedance analyzer
Study NCT05162183 — intervention group
Intervention type: DRUG
Intervention: Glimepiride
Description: Glimepiride dispensing claim is used as the reference group.
Study NCT05162183 — intervention group
Intervention type: DRUG
Intervention: Liraglutide
Description: Liraglutide dispensing claim is used as the exposure group.
Study NCT00181363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mamma board
Description: use of mamma board during radiotherapy
Study NCT03310723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face Mask preoxygenation
Description: Standard face mask preoxygenation.
Study NCT03310723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiFlow preoxygenation
Description: Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
Study NCT04435444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masterful supportive care
Description: Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)
Study NCT04435444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control supportive care
Description: Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)
Study NCT03300401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Receive intravenous injection just prior to ultrasound
Study NCT03300401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Receive intravenous injection just prior to ultrasound
Study NCT03300401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Ultrasound Imaging
Description: Undergo Contrast-Enhanced Ultrasound Imaging
Study NCT03300401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT03300401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT03300401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (90Y)
Description: Given IV
Study NCT03816735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cikatridina
Description: Women are asked to insert the suppositories according to the manufacturer's protocol.
Study NCT03816735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juliet Feminine Laser
Description: Women will receive the laser treatment twice during the study period.
Study NCT01179321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early referral to Dietitian for assessment and nutrition support
Study NCT01467141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected s.c. (under the skin) three times a day
Study NCT01467141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin
Description: Injected s.c. (under the skin) 30 minutes before the meals
Study NCT01467141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isophane human insulin
Description: May be administered s.c. (under the skin) in both treatment groups thrice daily
Study NCT01467141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isophane human insulin
Description: May be administered s.c. (under the skin) in both treatment groups thrice daily
Study NCT02431988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
Study NCT02431988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
Study NCT02431988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
Study NCT03147404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
Study NCT02512367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental care education program
Description: Dental care education program
Study NCT02512367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Surveillance
Description: Surveillance
Study NCT01553773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoflavone
Description: treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
Study NCT01553773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
Study NCT03090243 — intervention group
Intervention type: DEVICE
Intervention: Virtual colonoscopy
Description: Inserting a Foley catheter through the anus, and gas inflating of the bowel.
Study NCT02176213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg PO x 21 days
Study NCT02176213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: low dose cyclophosphamide 50 mg PO BID x 21 days
Study NCT02176213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
Study NCT02145234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089
Study NCT02431988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR19 T-Cells
Description: The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.~Three dose cohorts are planned:~* Dose Level 1: 2x105 CAR19 T-cells/kg~* Dose Level 2: 1x106 CAR19 T-cells/kg~* Dose Level 3: 5x106 CAR19 T-cells/kg
Study NCT01317758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03 Adjuvant
Description: Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
Study NCT01317758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Placebo/diluent provided by sanofi pasteur
Study NCT01317758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
Study NCT01317758 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sanofi H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
Study NCT03422029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate PRRT
Description: PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered.~Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT
Study NCT04737278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cunermuspir
Description: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:~Organic evaporated cane juice powder, hypromellose, titanium dioxide
Study NCT04737278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same non-medical ingredients and encapsulation as Intervention 1
Study NCT03453905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTFEA
Description: CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.
Study NCT03453905 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional decision algorithm
Description: Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
Study NCT00837915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
Study NCT00837915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
Study NCT00217425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days.~Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus.
Study NCT00217425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV infusion per institutional guidelines.
Study NCT00217425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
Study NCT00217425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone is taken orally.
Study NCT02145234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986089
Study NCT00217425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: IV push using extravasation precautions.
Study NCT00702858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blue Citrus
Description: Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
Study NCT00702858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
Study NCT00904813 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short-course RT
Description: Preoperative radiotherapy (RT) given 5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
Study NCT00904813 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long-course RT
Description: Preoperative radiotherapy (RT) given 2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
Study NCT00629226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00629226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00629226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00629226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Once daily, 5 days a week, for up to 8 weeks
Study NCT04415203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS)
Description: Patients in TAVNS group will receive TAVNS and usual care. TAVNS will be performed on Erzhong and Xin (Auricular Acupuncture Point with vagus nerve distribution) for 6 weeks by using the Huato type SDZ-V stimulator; Usual Care: usual medicine treatment for PVCs.
Study NCT04415203 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham-TAVNS)
Description: Patients in sham-TAVNS group will receive sham-TAVNS and usual care. Sham-TAVNS will be also performed on Erzhong and Xin (Auricular Acupuncture Point with vegas nerve stimulation) for 6 weeks by using a special Huato type SDZ-V stimulator. We cut the inner electric wire of the stimulator; therefore, there is no current output. Usual Care: usual medicine treatment for PVCs.
Study NCT02867267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Study NCT02867267 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of placebo every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Study NCT01395732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
Study NCT02335307 — intervention group
Intervention type: GENETIC
Intervention: CYP2D6 genotyping
Description: CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
Study NCT02335307 — intervention group
Intervention type: OTHER
Intervention: Pain assessment questionnaire
Description: A pain assessment questionnaire will be administered at baseline and 3 months.
Study NCT02335307 — intervention group
Intervention type: OTHER
Intervention: Physician assessment
Description: 20-item survey administered to physicians treating patients enrolled in the study
Study NCT04507607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.
Study NCT04507607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide 25 MG
Description: TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.
Study NCT02776111 — intervention group
Intervention type: OTHER
Intervention: Blood Sample
Description: A one time blood sample will be provided.